Marshall Wace LLP lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 104.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,946,954 shares of the company's stock after purchasing an additional 1,505,062 shares during the quarter. Marshall Wace LLP owned 0.40% of Roivant Sciences worth $34,862,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ROIV. Nordea Investment Management AB increased its stake in Roivant Sciences by 22.5% in the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company's stock worth $3,306,000 after acquiring an additional 52,031 shares during the last quarter. Barclays PLC grew its stake in shares of Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Retirement Systems of Alabama increased its holdings in Roivant Sciences by 26.9% during the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock valued at $6,116,000 after purchasing an additional 112,286 shares during the period. Elevate Capital Advisors LLC bought a new position in Roivant Sciences during the 4th quarter valued at approximately $2,116,000. Finally, Geode Capital Management LLC lifted its holdings in Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock worth $89,400,000 after buying an additional 1,460,205 shares during the period. 64.76% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
ROIV has been the topic of several recent analyst reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Monday.
Read Our Latest Research Report on Roivant Sciences
Insider Activity
In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 218,041 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at approximately $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,395,541 shares of company stock valued at $14,922,538. 7.90% of the stock is currently owned by company insiders.
Roivant Sciences Stock Up 1.4 %
ROIV traded up $0.16 during midday trading on Thursday, reaching $10.90. The company had a trading volume of 1,498,804 shares, compared to its average volume of 5,413,235. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The company has a market cap of $7.77 billion, a P/E ratio of -72.63 and a beta of 1.25. The business has a 50-day moving average of $10.33 and a two-hundred day moving average of $11.15.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
